Skip to main content

John Mascarenhas, MD

John Mascarenhas, MD
Videos
01/29/2025
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
John Mascarenhas, MD
Videos
09/12/2024
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
At the 2024 SOHO meeting, John...
09/12/2024
Oncology
John Mascarenhas, MD
Videos
09/12/2024
At the 2024 SOHO meeting, John Mascarenhas, MD reviewed the latest data in myelofibrosis treatment options, including upcoming novel combination and non-JAK inhibitor therapies.
At the 2024 SOHO meeting, John Mascarenhas, MD reviewed the latest data in myelofibrosis treatment options, including upcoming novel combination and non-JAK inhibitor therapies.
At the 2024 SOHO meeting, John...
09/12/2024
Oncology